Transporter-Targeted Prodrug Approach for Retina and Posterior Segment Disease

  • Andrea Burgess
  • Tanjm Azad
  • Nandish Pathak
  • Vipul Amin
  • Sheeba Varghese GuptaEmail author


Prodrug strategy is used to increase the bioavailability of drugs either by increasing the passive absorption by improving physicochemical properties of the parent drug or making them substrates of active transporter. There have been numerous reports and clinical applications of various prodrugs for oral delivery. Transporter-mediated prodrug approach is still a new and not completely explored area in the case of ocular delivery. This chapter gives a brief snapshot of the transporter-mediated prodrug approach for ocular delivery of drugs. There is also brief account of other types of prodrugs used for improving ocular bioavailability.


  1. 1.
    Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci. 2006;95(6):1177–95.CrossRefGoogle Scholar
  2. 2.
    Barot M, et al. Prodrug strategies in ocular drug delivery. Med Chem. 2012;8(4):753–68.CrossRefGoogle Scholar
  3. 3.
    Abet V, et al. Prodrug approach: an overview of recent cases. Eur J Med Chem. 2017;127:810–27.CrossRefGoogle Scholar
  4. 4.
    Bourges JL, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562–9.CrossRefGoogle Scholar
  5. 5.
    Thrimawithana TR, et al. Drug delivery to the posterior segment of the eye. Drug Discov Today. 2011;16(5–6):270–7.CrossRefGoogle Scholar
  6. 6.
    Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41(5):961–4.PubMedGoogle Scholar
  7. 7.
    Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for the drug development. Pharmacol Rep. 2013;65(1):1–14.CrossRefGoogle Scholar
  8. 8.
    Thakkar SV, et al. Stimulation of Na+/Cl--coupled opioid peptide transport system in SK-N-SH cells by L-kyotorphin, an endogenous substrate for H+−coupled peptide transporter PEPT2. Drug Metab Pharmacokinet. 2008;23(4):254–62.CrossRefGoogle Scholar
  9. 9.
    Casida JE. Why prodrugs and Propesticides succeed. Chem Res Toxicol. 2017;30(5):1117–26.CrossRefGoogle Scholar
  10. 10.
    Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design. Pharmacol Rev. 2011;63(3):750–71.CrossRefGoogle Scholar
  11. 11.
    Testa B. Prodrug research: futile or fertile? Biochem Pharmacol. 2004;68(11):2097–106.CrossRefGoogle Scholar
  12. 12.
    Shah SS, et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol. 2010;5(1):75–93.CrossRefGoogle Scholar
  13. 13.
    Dey S, Mitra AK. Transporters and receptors in ocular drug delivery: opportunities and challenges. Expert Opin Drug Deliv. 2005;2(2):201–4.CrossRefGoogle Scholar
  14. 14.
    Katragadda S, et al. Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells. Int J Pharm. 2008;362(1–2):93–101.CrossRefGoogle Scholar
  15. 15.
    Nashed YE, Mitra AK. Synthesis and characterization of novel dipeptide ester prodrugs of acyclovir. Spectrochim Acta A Mol Biomol Spectrosc. 2003;59(9):2033–9.CrossRefGoogle Scholar
  16. 16.
    Lee VHL. Membrane transporters. Eur J Pharm Sci. 2000;11:S41–50.CrossRefGoogle Scholar
  17. 17.
    Jain R, et al. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol Pharm. 2004;1(4):290–9.CrossRefGoogle Scholar
  18. 18.
    Patel K, et al. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int J Pharm. 2005;305(1):75–89.CrossRefGoogle Scholar
  19. 19.
    Janoria KG, et al. Vitreal pharmacokinetics of peptide-transporter-targeted prodrugs of ganciclovir in conscious animals. J Ocul Pharmacol Ther. 2010;26(3):265–71.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Andrea Burgess
    • 1
  • Tanjm Azad
    • 1
  • Nandish Pathak
    • 2
  • Vipul Amin
    • 2
  • Sheeba Varghese Gupta
    • 1
    Email author
  1. 1.USF College of PharmacyTampaUSA
  2. 2.Dr. B.B. Thakar Research CenterTampaUSA

Personalised recommendations